Skip to main content
Premium Trial:

Request an Annual Quote

Progenity to Raise $100M in Separate Public Stock, Private Senior Notes Offerings

NEW YORK ─ Molecular diagnostics firm Progenity said on Monday that it plans to offer $25 million of shares of its common stock in a public offering and $75 million of convertible senior notes in a separate private offering.

The San Diego-based firm is granting the underwriters of the public offering a 30-day option to purchase up to an additional $3.75 million common shares at the public offering price. Piper Sandler and Wells Fargo Securities are joint book-running managers and BTIG is the lead manager for the offering of common stock.

Separately, Progenity said it is offering to qualified institutional buyers convertible senior notes due in 2025 in an aggregate principal amount of $75 million and up to an additional $15 million as an option to the initial purchaser.

In November, Progenity said that it is trimming its workforce by around 10 percent and that a commercial insurer is seeking to recoup $27.4 million from the firm because of alleged overpayments.

The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.